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LETTER TO THE EDITOR
HER-2/neu oncogene: what does amplification mean?
Sir - The Her-2/neu oncogene amplification is a potential
prognostic marker in breast cancer. Therefore, its relation-
ship with several pathological and clinical parameters, useful
in the treatment decision process, has been widely studied.
Some authors reported an absence of association, others
associated HER-2/neu amplification with various items such
as the nodal involvement, histological grade, estrogen (ER)
and progesterone (PR) receptors, or survival (see review in
Allred et al., 1991). Although diverse, all these findings
always associated a poor prognosis indicator with HER-2/
neu amplification.
In a recent study initiated in our laboratory, the relation-
ship between HER-2/neu amplification and clinical or
tumoral factors (age, menopausal status, tumour size, his-
tological grade, nodal involvement and hormonal receptor
content) was assessed by slot and/or Southern blotting in 199
breast cancers (Descotes et al., 1993). For each sample, the
hybridisation signal was corrected for variations in the
amount of DNA blotted on the basis of the relative intensity
of the P globin probe. The degree of HER-2/neu ampli-
fication was evaluated by the ratio of the corrected signal for
the tumour DNA to the corrected signal for the leukocyte
DNA. A tumour was considered amplified when the cor-
rected ratio was equal to or higher than 2.0 for both tech-
niques. This cut-off value was selected on the basis of the
distribution of the ratios of the hybridisation signal for the
tumour DNA to the hybridisation signal of the leukocyte
DNA for the ,Bglobin, a gene known as usually unamplified.
This 2.0 cut-off value included 99.0% of the observed values
for the P globin gene. Overall, there were 33 amplified
tumours (16.6%) and an association between HER-2/neu
amplification and grade was found using univariate analysis
(X2 test, P value <0.05).
To try to reproduce some patient selections previously
reported, the main population was divided into several
subsets. The statistical test was carried out using the 2.0
cut-off value. In this new setting, a statistically significant
association was observed between the PR content and HER-
2/neu amplification in the pre menopausal, node positive and
pre menopausal node positive patients with P values of 0.02,
0.04 and 0.002 respectively.
Although this analysis was carried out using commonly
used methods, from the statistical point of view, it was far
from perfect. The choice of categorising a continuous
variable was motivated by the thought of a clinical use, i.e.
treatment or no treatment. However, it is known that this
might emphasise a given path especially if the variable used
to determine the cut-off value belongs to the same data
(Altman, 1992), as ,Bglobin in this series. Therefore, several
other cut-off values were tested. They were arbitrarily defined
rather than, as in the previous approach, based on the dis-
tribution of a reference probe. In this setting, the relation
with the histological grade was just significant only with a
cutpoint of 2.0 and then disappeared, whereas statistically
significant associations with the ER and the PR content were
detected only for cutpoints between 3.5 and 4.5 (Figure 1).
Furthermore, the 'best' observed P value varied: 0.046 for
the histological grade at 2.0, 0.02 for ER at 4.0 and 4.5 and
0.03 for PR at 3.5 and 4.5. Multiplying by the number of
cut-off values tested corrects the P value for the multiple
testing. In this case, the required P value to reach significance
is between 0.01 and 0.008 depending on the correction used
(Hilsenbeck et al., 1992). None of the associations previously
described met these requirements. However, as the intent of
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Figure 1 Variation of the statistical value of the observed cor-
relation between the HER-2/neu amplification and prognostic
factors according to the selected cut-off value in 199 breast
tumours. SBR histological grade (-* ), estrogen (- O) and
progesterone ( * ) receptor contents; the arrow indicates the
P = 0.05 limit for the statistical significance; the number of
amplified HER-2/neu tumours according to the cut-off value is
indicated in brackets.
this study was to try to understand the discrepancies in the
associations reported on in the literature, the uncorrected P
values could be used considering that each test was per-
formed by a separate investigator and was therefore unique.
This simulation has highlighted how the lack of standardisa-
tion of molecular biology techniques might contribute to
some of the discrepancies reported in the relevant literature
(Allred et al., 1991). The meaning of these differences may
solely be related to technical drawbacks or insufficiencies in
the statistical analysis but may also indicate differences in the
prognostic value according to the strength of the hybridisa-
tion signal, i.e. the number ofcopies of the gene, or may just
be informative on the severity of the DNA disorders.
These were obviously not the only pitfalls of these
analyses. Neither the slot nor the Southern blotting is able to
take into account the heterogeneity of the tumour samples.
In addition, as previously shown, the population selection
might reveal new correlations. However, it clearly emphasises
the need for a technical agreement based on inter centre
studies to define precisely what actually is amplification.
Another possibility is to standardise the statistical method-
ology to apply and the way to report the results.
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